Efficacy Study of Hydroxychloroquine to Treat High-risk Coronary Artery Disease.

• Status: Completed
• Trial end date: 2019-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate whether treated with hydroxychloroquine could improve therapeutic effect for patients with high-risk coronary artery disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University
• Treatments: Hydroxychloroquine

Criteria

Inclusion Criteria:

• Patients have been diagnosed coronary artery disease by coronary angiography or CT angiography.

• coronary artery disease with hypertension or diabetes or hyperlipidaemia(LDL>1.8mmol/L)

• High sensitivity C-reactive protein >1mg/L.

• On guideline-based secondary prevention of coronary heart disease medications≥1 months.

• No use of steroids, antibiotics, immunosuppressors a week before treatment.

Exclusion Criteria:

• Retinal disease.

• Chronic hepatopathy(ALT>120U/L).

• Renal dysfunction (eGFR<60).

• Moderately severe anemia, thrombocytopenia and leukocytopenia.

• Other contraindications for hydroxychloroquine.

• Active hemorrhage.

• Cancer or life expectancy< a year.

• New York Heart Association (NYHA) functional class≥class III, Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in plan.

• Pregnancy and lactation.